University of Texas at Tyler

Scholar Works at UT Tyler
MSN Capstone Projects

School of Nursing

Spring 4-19-2020

Controlled Donation After Circulatory Death: Benchmark Study
Marilyn R. Strait
Unversity of Texas at Tyler, mstrait2@patriots.uttyler.edu

Follow this and additional works at: https://scholarworks.uttyler.edu/nursing_msn
Part of the Bioethics and Medical Ethics Commons, Critical Care Nursing Commons, Nursing
Administration Commons, Other Nursing Commons, and the Perioperative, Operating Room and Surgical
Nursing Commons

Recommended Citation
Strait, Marilyn R., "Controlled Donation After Circulatory Death: Benchmark Study" (2020). MSN Capstone
Projects. Paper 17.
http://hdl.handle.net/10950/2614

This MSN Capstone Project is brought to you for free and open access by the School of Nursing at Scholar Works
at UT Tyler. It has been accepted for inclusion in MSN Capstone Projects by an authorized administrator of Scholar
Works at UT Tyler. For more information, please contact tgullings@uttyler.edu.

Running Head: CDCD CRITICAL PATHWAY

1

Benchmark Project: Critical Pathway for Controlled Donor After Circulatory Death
A Paper Submitted in Partial Fulfillment of the Requirements for

NURS 5382
In the School of Nursing
The University of Texas at Tyler
by
Marilyn Strait
Date 04/19/2020

CDCD CRITICAL PATHWAY
2
Benchmark Project: Critical Pathway for Controlled Donor After Circulatory Death
Few people want to discuss their own deaths, much less what they are going to do with
their bodies once their lives have ended. It is a crucial conversation, and one that can save lives.
Donation of one’s organs creates the potential for one of the most elusive gifts of all, more time.
The gruesome fact is that there are more people in need of organ transplants than there are
organs available. When supply and demand become a life or death situation, it brings on a whole
new view to the business of healthcare. Temper that with the knowledge that living donors are
not possible for all types of needed organs, and it becomes even more poignant. An estimated
113,000 Americans, 3,100 of whom are Ohioans, are in need of a life-saving transplant at this
time (ODH, 2019). An average of 20 people dies in the United States each day waiting for an
organ that never arrives (ODH, 2019). Every failed attempt to procure organs from a potential
donor means up to a potential eight lives lost and fifty lives not improved (MedlinePlus, 2020).
In that vein, the transplant community is seeking to expand all viable means of organ
transplantation. As a small subset of all donation after circulatory death donors, the Maastricht
III classification, or controlled donation after circulatory death (cDCD) population is the most
viable of all DCD donors. It is thus an excellent population upon which to focus improvement
efforts. Though riddled with potential for ethical dilemma, it has promise to significantly
improve this deficit of treatment (Daemen, Koostra, Wijnen, Yin, & Heineman, 1994; Evrard,
2014). This benchmark proposal seeks to resolve the current barriers in place for addressing this
particular population through the veil of a Toledo, Ohio hospital, Trauma-level One hospital, as
an ideal exemplar for the types of large hospitals which should receive this intensified focus
(TJC, 2004). It will serve as a template for expansion into similar hospitals in the United States
struggling with the same issue.

CDCD CRITICAL PATHWAY
3
Rationale
ProMedica Toledo Hospital is a 700-plus bed, Trauma-One Level Hospital located in
downtown Toledo, Ohio. This is the primary acute care hospital for the region, and as a large
hospital, is the prime location for organ procurement (OP) efforts for this region (TJC, 2004).
This facility is suffering from several setbacks in this effort, however. The staff has ethical
concerns related to the potential for comfort care to hasten death, all levels of leadership have
ethical concerns with the level of the organ procurement organization’s (OPO) and organ
procurement coordinator’s (OPC) involvement in the pre-death care of potential cDCD donors,
and there is little direction outside of the OPO on the best practices for the process of OD in this
population. This trifecta has converged into sufficient discomfort with the program to improve
it. With lives on the line, all good-faith efforts to create a structured, equitable and standardized
system for the procurement of organs is the ethical and moral decision in this community. To
address this problem, the following PICO question was formed: In potential organ donors after
circulatory death (P), does the utilization of an evidence-based critical pathway from
identification of potential donor to organ procurement (I) versus no utilization of an evidencebased critical pathway (C) increase the rate of organ procurement and the satisfaction of donor
families with the donation process (O)?
Literature Synthesis
Critical Pathway
The utilization of an evidence-based critical pathway (EBCP) in the management of a
potential cDCD donor through the procurement of organs is a widely recommended means by
which an evidence-based template for action may be applied to the real world setting of the
acute-care hospital (CCM & ETA, 2017; IOM, 2000; TJC, 2004). This is most readily achieved

CDCD CRITICAL PATHWAY
4
through the utilization of the EBCP created by five of the leading organizations within the
transplant industry. (See Appendix A.) However, each hospital has unique barriers, cultures,
and needs that must be addressed for such an EBCP to work. This EBCP addresses much of the
federal requirements, but cannot meet the needs of each individual state and regional needs
within one document. Thus, the individualization of this EBCP is highly recommended. Due to
the many potential ethical dilemmas created, the paramount being the moral and ethical
obligation not to violation the “dead donor rule,” (a donor must not be killed by the harvest of an
organ) and the requirement that organs be anatomical gifts (that no one may purchase a human
body organ), there is unsurprisingly much legislation and regulation surrounding the topic (CMS,
1993). It is essential to be aware of the laws and regulations surrounding the cDCD process for
any change to be appropriate and sustained.
Laws and Regulations
The Ohio Administrative Code , states that a hospital intending to procure organs for
transplant must have an existing contract with their regional OPO, and must have written policies
and protocols for organ transplantation that address amongst other issues inclusion of the
primary care physician (PCP), a thorough education of the patient (or their agent), and detailed
plans for the management of each OP attempt (SOO, 2017). There may be caveats in the
contract between the OPO and the health care organization (HCO) as well as within a particular
state’s laws which must be addressed in order for the implementation to be lawful, though no
contract may supersede the law. The Centers for Medicare and Medicaid (CMS) also assist in
the regulation of this process. If an HCO is utilizing the Joint Commission (TJC) for deemed
status, their requirements will be even stricter. Generally speaking, these requirements include
the necessity for: a written agreement between the OPO, a tissue bank and the HCO; cooperative
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interaction between the parties in the review of data regarding the OP rates and program
successes or failures; that the hospital has a written policy and procedure for its OP attempts; that
the staff is educated to the technical, ethical, and cultural components of an OP attempt; that
records are maintained on every attempt; that the hospital and OPO are standardized in their
approaches to the OP attempts; that all tissues are able to be traced bi-directionally; and that all
adverse events are investigated by the hospital (CMS, 1993; TJC, 2020).
Family and Staff Satisfaction & Donation Rates
The family is often the agent for the potential cDCD donor at time of consideration for
OD. During such an emotionally traumatic time, it is difficult to assure that informed consent is
occurring. This consent is essential to the ethical procurement of organs and must be attended.
Incorporation of the family in the holistic view of the patient, focused and repetitive education,
and continual assessment of their understanding is key to meeting the ethical obligation of
informed consent. Additionally, the concerns that staff may have, whether due to a lack of
knowledge on cDCD care or a valid crossing of ethical boundaries, may cause significant moral
distress and lower their support of cDCD (AOPO, AST, ASTS, NATCO, & UNOS, n.d.;
Berntzen & Bjork, 2014; Dorflinger, Auerbach, & Siminoff, 2012; Ledoux et al., 2014;
Neidlinger, Gleason, & Cheng, 2013; Philpot, Aranha, Pilcher, & Bailey, 2016; Prins & Human,
2019; Scott & Quick, 2012; Sidiropoulos et al., 2016; Smith, Leslie, & Wanden, 2015; TJC,
2004). It is essential that the staff involved in the education and consent process with the family
of a potential cDCD donor continually educate to and assess the family’s comprehension of
ongoing tests, time between decision and withdrawal of life-support treatment (WLST), and
general expectations to assure that the family ultimately perceives the process of donating their
loved one’s organs positively (Berntzen & Bjork, 2014; Dorflinger et al., 2012). Additionally, it
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is important to affirm with the family and the staff involved in the process that the donor is seen
as a whole individual, worthy of the highest care possible. One such method which had
promising effects on staff and family was the implementation of a short patient-centered
statement and a fifteen-second moment of silence to honor the donor prior to the WLST
(Neidlinger et al, 2013; Smith et al., 2015). One may improve the family’s satisfaction and the
OP rate by the OPC having a frank conversation about the benefits and basic principles of organ
donation prior to asking them for a determination of whether to participate (Philpot et al., 2016;
Prins & Human, 2019). An important note is that the breakdown of an EBCP process was shown
to decrease OP rates, and as such a strong, well-incorporated EBCP is essential to sustained OP
program success (Razdan, Degenholtz, Kahn, & Driessen, 2015). Additional measures found to
increase OP rate and family satisfaction included culturally sensitive communication styles,
which include an individualized reflection of the types of conversation utilized by the potential
cDCD donor’s family (Scott & Quick, 2012; TJC, 2004). At its core, cDCD efforts should focus
on the family patient, if OD is to be successful.
Comfort Care and Ethical Perspectives
There is an ongoing debate about the ethicality and morality of inclusion of pre-mortem
measures, which yield no benefit to the donor, but may increase the viability of organs procured
through the cDCD process. Currently the resounding message is that if these measures are
employed with an additional, separate consent of the family, they remain ethical (CCM & ETA,
2017; Sidiropoulos et al., 2016). Another common concern of staff is the utilization of comfort
care medications and their potential to hasten death in this population. Comfort care medications
(anticipatory utilization of intravenous pain medications such as fentanyl and sedatives such as
midazolam) do not hasten death when used similarly to levels utilized in end-of-life care
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(Ledoux et al., 2014; Wind et al., 2012). It is essential to disseminate this information to staff
involved in the OP process, as this concern is likely to negatively affect staff perceptions of OP
attempts, particularly in those who are not as familiar with the dying process.
Prediction to Death and Warm Ischemic Time
One of the biggest clinical drivers within the OP attempt in the cDCD population is the
struggle to maintain organ viability by reduction of the warm ischemic time (WIT), or the time
between declaration of death and OP. This is largely attributed to the limited ability to
accurately predict time to death after WLST. Studies of the topic are typically of small sample
size and measure varying factors which may confound results. The EBCP implements an
amalgamation of the best current evidence on which clinical factors to observe for the likeliest
correct prediction of death within 60 or 120 minutes. The idealized WIT (e.g. 60 versus 120
minutes) is dependent upon which organ is being procured, but generally speaking it is more
common for prediction models to utilize the 60 minutes marker, as it encompasses the greatest
likelihood of procurement of the most viable organs. Accordingly, this cut-off will be the
primary focus of this discussion. The best indication of death within 60 minutes is the necessity
of controlled mechanical ventilation, particularly when the required 𝐹𝑖𝑂2 is less than or equal to
fifty percent (AOPO et al., n.d.; Lewis et al., 2003; Munshi et al., 2015; Rabinstein et al., 2012;
Wind, Snoeijs, & Brugman, 2012). However, the following indicators also have a reasonable
prediction of death within 60 minutes and should be considered when in conjunction with the
former: dependence on pacemaker, ventricular assistive device, inotropic medication or the
vasopressor norepinephrine; physician opinion of imminent death; Glasgow Coma Scale score of
less than five while free from the effects of any pertinent sedatives; and a persistent 𝑆𝑎𝑂2 of less
than or equal to 92 percent (AOPO et al., n.d.; Lewis et al, 2003; Munshi et al., 2015; Rabinstein
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et al., 2012). The following indicators in addition to or where duplicated in opposition to the
afore-mentioned factors have a less reliable, but still notable ability to predict death within 120
minutes: 𝐹𝑖𝑂2 greater than or equal to 70 percent; absence of cardiovascular comorbidity (AOPO
et al., Lesieur, Leloup, Gonzalez, & Mamzer, 2014; Wind et al., 2012). It is important to note
that in all of these studies, the best sensitivity and specificities noted for any individual or
combined factors never reached 90 percent (Lewis et al., 2003; Lesieur et al., 2014; Munshi et
al., 2015; Rabenstein et al., 2012; Wind et al., 2012). Thus, the accurate prediction to death
within 60 minutes with the intent of reduction of WIT and thereby increase of viable OP is an
ongoing pursuit worthy of additional research. What is consistently true throughout the
literature, is that an HCO should implement a well-planned, well-structured, individualized,
consistently utilized EBCP for the procurement of organs in the cDCD population to ensure
optimal outcomes for all factors mentioned.
Stakeholders
Directly Affected.
It would be imprudent and indeed short-sighted not to list the potential donors and their
families first amongst those who are affected by this proposal. It is essential in the
standardization of healthcare behaviors, that HCOs and their personnel never lose sight of the
profound gift these individuals are offering. They are seeking to create good out of tragedy, and
anything less than best, evidence-based efforts neglect this sacrifice. Transplant recipients are
additionally affected by the process, and as such it is important that the EBCP includes evidencesupported processes with the likeliest outcome of viable organs that maintains itself within the
confines of ethical procurement. Additionally, the primary care physicians, critical care
intensivists (or their designees who would be performing the determination of death), the OPC,
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the intensive care nurses who participate in the pre-death care, the OR staff including surgeons
who participate in the post-mortem procurement, and the staff development department, or
education department who would be involved in the dissemination of this change in process are
all directly affected by the implementation of the EBCP. As such, all efforts should be focused
on assuring that the concerns of these stakeholders are incorporated into the individualization of
the EBCP.
Indirectly Affected.
Those indirectly affected, but in greatest position to support or terminate this change
proposal would be the c-level suite executives. A primary focus on the key stakeholders Chief
Nursing Officer and Chief Medical Officer would be prudent, as they are the leaders of the staff
most affected by the process. Additionally, the Chief Anesthesiologist would be a key
stakeholder-informant to the process (CCM & ETA, 2017). Other potential stakeholders who
should be included in the initial individualization of the EBCP include: the OPO and OPC; the
transplant program manager; the hospital’s risk management leader; and any nursing director
who presides over intensive care units, with particular attention paid to the cardiovascular
intensive care unit director(s). These individuals support of or opposition to this change will
greatly affect the outcome of the implementation. Thus, it is essential to garner buy-in from
these groups by allowing them opportunity to provide feedback and champion the components of
the EBCP most pertinent to their roles.
Planned Implementation
Phase One: Research & Development
The implementation of an EBCP for the cDCD population will follow the foundation of a
phase-gate project management structure, utilizing the components of the project life cycle to
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maintain consistent stakeholder interest and participation in the change process. Each gate will
be utilized to assure at the end of each phase that the project continues to meet the HCO’s values,
mission, and goals before continuing on to the next phase.
Gate 0 is the initial agreement to initiate efforts to improve the cDCD process through the
utilization of the EBCP. The initial phase will consist of an evaluation of the stakeholders’
perceptions of the current cDCD program and synthesis of the current body of knowledge for
EBCP utilization for the cDCD population. The literature review presented herein is the starting
point from which the HCO should expand its individualized information needs. A baseline of
the staff’s current concerns and the facility’s current procedures will assist in illuminating the
gaps between current practice and best practice. Identification of the educational needs of the
HCO is essential in this phase. For the exemplar Toledo Hospital, educational needs were
compartmentalized into four main topics: ethical issues surrounding cDCD; the EBCP process;
family-centered care within the context of a cDCD donor OP attempt including current
knowledge on comfort care for this population; and regulatory guidelines review for the OP
process. The recommendations in this project, therefore reflect these individualized needs and
while site-specific, also address many of the national topics which are ideally addressed in
similar sites’ endeavors. At the end of this phase, all data will be shared with minimally the key
stakeholders for recommendation of additional educational components and approval to proceed
through Gate 1 onto Phase 2.
Phase Two: Plan Individualization
During this phase, the staff development (education) team will be heavily utilized to
convert the education topics into staff-friendly education modules, based on the individual
HCO’s needs. The pre-test and first of two total post-tests should be created at the time of the

CDCD CRITICAL PATHWAY
11
education modules. An example of questions to include in the tests, based upon the exemplar
hospital is included in the data collection section, following. However, the focus of the
assessment should be on the individual educational needs of the HCO to which this project is
applied, the staff support of the cDCD process, the EBCP itself, and the ethics of cDCD overall.
An expert panel including minimally the Chief Anesthesiologist and staff development
team will review the EBCP proposed and make any recommendations for individualization
necessary to assure the EBCP will meet the needs of the populations served. Additionally, the
panel will make final determinations on which predictive tool will be utilized in the prediction of
time to death, as few have been externally validated to the degree necessary to have a strong
evidentiary support (Munshi et al., 2015). This further requires stakeholder engagement in the
selection process. It not only is prudent to include these individuals for their specific knowledge,
it is an essential component to assuring their buy-in to the change process. Allowing them to be
a part of the project at each gate fosters their ownership in the project and provides opportunity
for those with the most pertinent knowledge to engage in laying the foundation to the project’s
success. Gate 2 provides a structured stopping point to confirm the individualization of the
education and EBCP meets the mission, values and goals of the HCO.
Phase Three: Education
During this phase, staff will be educated on the EBCP which was adapted to the
individual needs of the facility and cDCD population of the HCO’s region during the previous
phase. In the exemplar, the education focuses on the afore-mentioned four core issues in
response to and in anticipation of the greatest barriers to change implementation success. This
sub-phase is expected to take two weeks. Individualization efforts in Phase 2 are reflected here.
The Toledo Hospital requires education to: the EBCP process, the Centers for Medicare and
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Medicaid, Ohio Administrative Code, and The Joint Commission laws and regulations governing
cDCD process; and the ethical foundation of cDCD with a focus on the safety and morality of
providing comfort care due to their site-specific concerns and hesitations. A pre-test and initial
post-test are administered during this phase, immediately before and after the education is
provided to the staff. The data collection effort is divided between the HCO and the OPO. The
education-based data (test results which include both staff perceptions of the cDCD process as
well as cDCD facts) are collected by the HCO during this phase. The OPO will collects data
related to the clinical success of the implementation of the EBCP and family satisfaction with the
cDCD process during the next phase, implementation. OPOs are required by law to collect and
share certain metrics, discussed in the data collection section, as they are reportable to the
government. As such, they are the ideal mechanism through which to collate this data. The
progress of the project will be reviewed at Gate 3 and if approved, the project will proceed to
Phase 4.
Phase 4: Implementation
During the implementation phase, the roll-out of the true EBCP project will begin. When
a potential cDCD donor is identified, the EBCP will be initiated and utilized by staff to assist in
the OP attempt. The EBCP proposed includes space for individualization to family needs, as is
necessary in all evidence-based projects. The change champion will monitor outcomes with
stakeholders in debriefings after each cDCD OP attempt to identify any unforeseen barriers and
address with the stakeholder team accordingly. One specific holistic recommendation that is
included in the education and implementation subphases, but not listed in Addendum A is the
incorporation of a moment of silence prior to WLST. Evidence supports this particular modality
of donor recognition increases family satisfaction with the donation process and a defined
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structure for donor recognition assists in the reduction of moral distress for staff involved in the
cDCD OP process (Neidlinger, Gleason, & Cheng, 2013; Smith, Leslie, & Wynaden, 2015).
Preliminary findings and barriers noted during this phase will be discussed and addressed with
the stakeholders at Gate 4 before initiation of the final phase, Evaluation.
Phase 5: Evaluation
The final phase, Phase 5, will be utilized to evaluate the effectiveness of the
implementation of an EBCP in the family and staff satisfaction outcomes as well as the OP
outcomes as compared with the previous baseline. A final post-test will be administered to
verify what knowledge the staff retained throughout the change process. It will be subject to
some bias, as repeated exposure to the test will increase retention of the material therein. An
increase in OP will be an obvious identification of project success, however, increased staff
willingness to participate in the OP process and continued or improved expressions of family
satisfaction with the OP process will also mark success for the change project. It is essential that
a family-as-patient, holistic mindset be incorporated not only throughout the planning and
implementation phases of this project, but that it also be employed in the evaluation of any
process improvement which affects patient family lives. Data collected will be aggregated,
contrasted against comparable metrics, and presented to the stakeholders at Gate 5. This
terminates the change process and further revisions or performance improvement measures are
recommended to be addressed in a plan-do-study-act cyclical fashion, with a maximal
interspacing of annual reviews between cycles.
Timetable / Flowchart
As previously noted, a phased-gate process will be followed to ensure stakeholder
inovlvement throughout the change process. (See fig.1) A minimum of three to four months
should be utilized in the process to assure an effective transition to the new processes. The first
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phase should last approximately two months, and is the longest phase of the 5-phase process.
This is because a well-researched understanding of the HCO’s local and national laws and
regulations governing the process must exist if the individualization of the EBCP is to occur in
the second phase. It would be important to have the stakeholders identify their common
concerns such that education needs are identified prior to the second phase, as well. As is
common to phase-gate project management, each phase is initiated by a gate, where the
stakeholders must agree to continue with the process or the project is terminated. It may seem
cumbersome or bureaucratic to employ this method, but it is a key component to assure
continued awareness of the project and agreement to its progress and components by
stakeholders. The first gate (Gate 0) was the agreement to undertake this project. The second
gate (Gate 1), which lies between Phase 1 and Phase 2, will mark the point at which the
stakeholders, primarily those indirectly affected, will identify any needs or agree to continue
with the plan for individualization after receiving a summation of the current data. Depending
on ther level of involvement and the HCO’s environment, they may choose to participate in
Phase 2 in a more direct manner.
During the second phase, the EBCP and education plans will be individualized to meet
the HCO’s internal and external boundaries and needs. This is the second-longest stage of the
process, because it is the time when the EBCP and education are to be tailored to the prioritized
focus and organizational constraints specific to the HCO undertaking this process, which is timeconsuming if done properly. The individualized EBCP should be incorporated into the policy
and procedure of the organizaton as an appendix to assure its sustained utilization throughout the
organizatoin. Once the EBCP has been individualized to meet the abilities of the HCO and to
assure consistency with the HCO’s mission, values, and goals, it enters the third gate, (Gate 2).
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It is here that the individualized EBCP is reviewed by the indirectly affected as well as select
members of the directly affected (e.g. managers of the education department or directors of the
intensive care units), appropriate to the HCO’s structure, are included in the approval,
recommendation for revision, or rejection of the project. This would be the key time to assure
the approval of the amended policy and procedure document through whathever bodies
necessary.
Assuming it is approved to continue, (staff) education is the next phase implemented. It
should be rolled out no shorter than over two weeks, though a longer implementation of this
phase is recommended where possible. This allows for the individualized EBCP and HCOspecific needs-focused information is disseminated to the staff. A pre-test, part of the evaluation
phase, should be administered prior to the education to help identify what the true baseline of the
staff was prior to their education. Additionally, an immediate post-test should be administered
after the education dissemination. Please see the evaluation section for more detail on the pretest and post-test components, which include subjective and objective assessments.
The fourth gate (Gate 3) will reflect a review of the pre- and post-test results and a
sharing of the content included in the education with a focus on the EBCP and how this
structured, standardized approach is current best evidence to support OP efforts. The education
should be tailored to address which topics are of greatest concern to the directly affected
stakeholders and reflected at this Gate’s review. Once approved, the project would enter the
Implementation phase, or Phase 4.
In this phase, the EBCP would be operationalized. A minimum of a month is
recommended, due to the relative infrequency of these types of cases. If six months of data is
possible to be obtained before progressing to the next gate, it is highly recommended. Once
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sufficient data regarding the utilization of the EBCP is achieved (a minimum of 10 attempted
donations is recommended), the data collected can be evaluated at Gate 4.
The final phase of the implementation is the evaluation. A final post-test, a duplicate of
the initial post-test should be administered at the onset of this phase. These results should be
compared against the pre-test and post-test administered in Phase 3, along with metrics
associated with the OP rates and any family feedback received by managers throughout the
implementation phase. It is here that the data is collated, reviewed and preparred for
dissimination with recommendations for future actions and the initiation of a plan-do-study-act
cycle should be initiated to sustain improvements in OP rates, family satisfaction, and any other
key individualizations noted in the plan from Phase 2. Finally, at Gate 5, the information should
be disseminatied to all organizationally pertinent stakeholders to show if and to what level the
EBCP utiliztaion and its corresponding education positively affected OP rates, and staff and
family satisfaction.

(Figure 1. Timeline and Flowchart of EBCP Implementation Plan)
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Data Collection Methods / Planned Evaluation
Data collection should regard two major components of the project, the education to and
the effectiveness of the EBCP. Education outcomes can most readily be collected by the
utilization of a pre-test, post-test mechanism. The recommended staff education outcomes to
measure within this test is a 5-point Likert-scale evaluation of the following topics: level of
agreement with the ethical and moral stance of OP; and level of agreement with willingness to
participate in OP practices at the HCO. More objective measurements that are recommended for
inclusion, assuming they meet the individualized education of the HCO, include: agreement with
the statement that comfort care measures do not hasten death; accurate understanding of the
“dead donor rule;” accurate correlation between the Maastricht III and the cDCD population;
appropriate manner for escalation of ethical concerns within the hospital; and three key
indicators for an increased accurate prediction of time to death within 60 minutes, as noted on
the EBCP. An improvement in the aggregate from pre-test to first post-test indicates a response
to the education provided. An improvement or maintenance of similar aggregate scores between
the first and second post-test indicates a sustained knowledge retention and reinforcement of key
principles through the utilization of the EBCP as well as increased organizational involvement in
the changed process.
It is standard for certain metrics to be collected by the OPO and shared with the HCO, as
they are required by federal and many state laws to collect and report these OD-related data.
They include: donor identification rates (rate the HCO staff identifies a potential donor within
one hour of meeting the potential donor criteria); donor conversion rates (number of potential
donors who become organ donors); and OP rate (number of viable organs, skin tissue, eyes,
etc.…per donor). It would be prudent, therefore, not to reinvent the wheel in the measurement of

CDCD CRITICAL PATHWAY
18
the EBCP’s success. Utilize the baseline data from as many months as the implementation
covers, prior to the implementation of the EBCP, as a comparison against the data for the
implementation period. Any improvements can be attributed to the utilization of and training
about the EBCP.
Cost / Benefit Discussion
Resources
Resources are fortunately easily controlled in this change process. All stakeholders
mentioned above have agreed to engage in the change process or process improvement attempt
via the implementation of an EBCP, which they have further agreed to participate in
individualizing to their facility and populations served. The staff development department
within the HCO will be utilized to disseminate education to address current deficiencies in the
staff understanding of the evidence-based practices and current body of knowledge. As this
education is already a legal requirement for any OP facility, it is considered within the existent
budgetary constraints and labor hours the HCO will incur. The testing can be administered with
the education and by the change champion. Considering the risks of a poor versus excellent
reputation for OP within the community, it is well worth the relatively minor increase in one
staff member’s workload.
Costs
Currently, the cost of the attempt for OP should rest upon the OPO. This is a standard
component of most contracts between OPOs and HCOs, as it is required by law (CMS, 1993;
SOO, 2017). As there should be no perceived financial benefit from the ORG in the
procurement of organs, whose staff is involved in the cDCD donors’ end of life determinations
and care, the OPO will remain the responsible party for the costs and benefits associated with the
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procurement of organs. The costs of the OP program will be negotiated independently of the
change process between the HCO and the OPO and are outside the scope of this project. The
implementation of an EBCP is anticipated to increase efficiency and staff support of the
program, and as such does not have readily anticipated increases to current costs beyond those
required to educate staff. As education to these processes are mandated by regulatory bodies, it
is not considered an increase to current expenditures, either. All costs associated with labs or
diagnostic procedures are paid by the OPO, per current policy. The donor family is not charged
for the attempt to procure organs from their loved one, per law (CMS, 1993; SOO, 2017.
Discussion
Discussion
The Coronavirus-19 pandemic swept through the country during the attempted
implementation of this project, causing a conversion to a benchmark project. However, key
lessons learned during this project are reflected herein. To assure stakeholder buy-in, utilize an
implementation process such as a phase-gate project management model, which incorporates
stakeholders into the design. This encourages all levels of stakeholders feel ownership of the
change process. Incorporate the EBCP into the HCO’s policies and procedures. This engrains it
into the fabric of the HCO’s processes, assisting in its sustainability. Education should address
some basic issues, such as the legal, ethical and logistical components of organ donation in this
unique population. Educating staff to the process and surrounding foundation for cDCD helps
foster their support of cDCD OP attempts, which further supports OP rates, particularly when
education focuses on appropriate staff interactions with donor families and appropriate use of
comfort care measures. However, it must be individualized to the specific HCO’s needs and
potential biases for or against the process.
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The use of an EBCP standardizes and thereby structurally supports the ethical boundaries
and logistic needs of an attempted cDCD OP. Equitable treatment of all potential donor and
donor families via a standardized approach also supports the necessary ethical confines of this
OP process. The use of an EBCP increases OP rates in an ethical manner that helps meet
everyone’s ultimate goal of extending transplant recipients’ lives.
Finally, it is essential to recognize that timing is integral to any change process. Read
the room. If the HCO is facing severe external constrains on its resources, this may not be the
best time to implement. That doesn’t mean it should never occur, but evidence-based practice
must always have the patient at its core. If the HCO is not meeting the needs of the patient
population, it’s not doing its ethical and moral obligation to its community. Desire to do good
for one’s community only extends as far as its usefulness to that community.
Conclusion and Recommendations
In summary, the findings of this benchmark project inform the recommendations to use
an individualized EBCP for OP within the cDCD population. Incorporate holistic donor familypatient practices into the EBCP to increase family satisfaction and assure informed consent.
Education of the staff and donor family are key components to the EBCP’s success.
Incorporation of the EBCP into the HCO’s policies and procedures further engrains it into the
HCO’s practices and culture. Utilization of a phase-gate project management structure for the
change process supports the sustained involvement of stakeholders to the change process and
thus increases buy-in. The end-goal is the facilitation of a meaningful gift between donors and
families experiencing tremendous tragedy to help avert the same for others. All reasonable
measures to maximize the potential of these gifts of time are the ethical and moral obligation of
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HCOs. Implementation of an EBCP is a structured, standardized and well-supported mechanism
to meet this goal.
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